Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Xiaflex Prior Auth | OpenPayer
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield of TennesseePolicy ID_CHS_30432026_1126

    Collagenase Clostridium Histolyticum (Xiaflex)

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_30432026_1126 alerts

    Get alerted when Policy ID_CHS_30432026_1126 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization requirements for Xiaflex in adult members with Dupuytren's contracture or Peyronie's disease, including clinical criteria, documentation, administration, and quantity limits.

    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyCollagenase Clostridium Histolyticum (Xiaflex)
    Policy CodePolicy ID_CHS_30432026_1126
    Change TypeNo material change
    Effective DateJan 30, 2027
    Next Review DateN/A
    Key ActionSubmit diagnosis-specific chart notes or medical records and, for continuation requests, the member's total number of prior injections for prior authorization review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered FDA-approved indications
    3Maximum injections per Dupuytren's cord
    8Maximum Peyronie's treatment-course injections
    ExcludedCosmetic use

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 or 12 mo
    Authorization periods
    TNMandate jurisdiction

    Coverage Criteria

    Initial therapy: Dupuytren's contracture

    Authorization for 6 months may be granted when all of the following criteria are met.

    Initial Dupuytren's contracture criteria

    • Clinical and treatment requirements

      • Contracture with palpable cord: The member has a finger flexion contracture with a palpable cord in a metacarpophalangeal joint or a proximal interphalangeal joint before initiating Xiaflex therapy.
      • Minimum contracture: The contracture is at least 20 degrees before initiating Xiaflex therapy.at least 20 degrees
      • Positive tabletop test: The member has a positive tabletop test before initiating Xiaflex therapy.Unable to simultaneously place the affected finger(s) and palm flat against a table
      • Adult age: The member is 18 years of age or older.>=18 years
      • Injection limit: The member will receive no more than 3 injections per cord, administered 4 weeks apart, as part of the current treatment.up to 3 injections per cord, 4 weeks apart

    Initial therapy: Peyronie's disease

    Authorization for 12 months may be granted when all of the following criteria are met.

    Initial Peyronie's disease criteria

    • Stable disease: The member has stable Peyronie's disease without clinical changes, such as worsening curvature, for at least 3 months.stable for at least 3 months
    • Plaque and curvature: The member has a palpable plaque and curvature deformity of at least 30 degrees and no more than 90 degrees before initiating Xiaflex therapy.30-90 degrees
    • Intact erectile function: The member has intact erectile function, with or without medication.

    Continuation therapy: Dupuytren's contracture

    Authorization for 6 months may be granted for continuation when all of the following criteria are met.

    Continuation Dupuytren's contracture criteria

    • Meets coverage criteria: The member meets all requirements in the coverage criteria section.
    • Same treatment course: The member is continuing a treatment course for the same cord. Treatment of a new cord or a previously treated cord following recurrence requires meeting all coverage criteria requirements.
    • Remaining injections: The member has received fewer than 3 injections total per cord, administered 4 weeks apart.less than 3 injections per cord; 4-week intervals

    Continuation therapy: Peyronie's disease

    Authorization for 12 months may be granted for continuation when all of the following criteria are met.

    Continuation Peyronie's disease criteria

    • Meets coverage criteria: The member meets all requirements in the coverage criteria section.
    • Continuation curvature: The member has curvature deformity of at least 15 degrees at the time of the continuation request.at least 15 degrees
    • Remaining injections: The member has received fewer than 8 injections total, including injections received during any previous treatment.less than 8 total injections

    Tennessee mandated off-label coverage

    Off-label use is subject to Tennessee mandate requirements when all applicable conditions are met.

    Mandated off-label coverage conditions

    • Recognized evidence source: The off-label use is recognized in a statutorily recognized standard reference compendium or in published peer-reviewed medical literature.

      Either source category satisfies the evidence-source condition.

    Cosmetic use, including cellulite reduction treatment, is excluded from coverage.

    Coverage is not provided for indications other than the specified FDA-approved indications. Such uses are considered experimental, investigational, and not medically necessary.

    Coverage is limited to the specified FDA-approved indications: adult patients with Dupuytren's contracture and a palpable cord, and adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. All other indications are considered experimental, investigational, and not medically necessary.

    Initial Therapy

    Dupuytren's contracture initial therapy

    Authorization for 6 months may be granted when all of the following criteria are met.

    • Contracture with palpable cord: The member has a finger flexion contracture with a palpable cord in a metacarpophalangeal joint or a proximal interphalangeal joint before initiating Xiaflex therapy.
    • Minimum contracture: The contracture is at least 20 degrees before initiating Xiaflex therapy.at least 20 degrees
    • Positive tabletop test: The member has a positive tabletop test before initiating Xiaflex therapy.Unable to simultaneously place the affected finger(s) and palm flat against a table

    Continuation Therapy

    Dupuytren's contracture continuation

    Authorization for 6 months may be granted for continuation when all of the following criteria are met.

    • Meets coverage criteria: The member meets all requirements in the coverage criteria section.
    • Same treatment course: The member is continuing a treatment course for the same cord. Treatment of a new cord or a previously treated cord following recurrence requires meeting all coverage criteria requirements.
    • Remaining injections: The member has received fewer than 3 injections total per cord, administered 4 weeks apart.less than 3 injections per cord; 4-week intervals

    Clinical Thresholds

    Dupuytren's Contracture Threshold
    ConditionDupuytren's contracture
    Minimum flexion contractureAt least 20 degrees
    Assessment timingPrior to initiating Xiaflex therapy
    Peyronie's Disease Initiation Threshold
    ConditionPeyronie's disease
    Curvature at initiationAt least 30 degrees and no more than 90 degrees
    Assessment timingPrior to initiating Xiaflex therapy

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Submission Required

    Submit prior authorization documentation for the applicable indication before initiating Xiaflex review. For continuation requests, include the required continuation records and the member’s injection history.

    • For new starts, submit diagnosis-specific chart notes or medical records supporting the applicable clinical criteria.
    • For continuation, document that the member meets the coverage criteria, is continuing the treatment course as applicable, and has received fewer than the permitted number of injections.
    Documentation Required

    Clinical Documentation

    Clinical documentation must support the diagnosis and treatment request for the applicable indication. Include the specified findings for both new starts and continuation requests, along with the number of injections received for continuation.

    • Dupuytren's contracture: Chart notes or medical records indicating the affected joint, contracture, and a positive tabletop test for new starts and continuation; for continuation, also document the number of injections the member has received.

    Policy Background

    Xiaflex (collagenase clostridium histolyticum) is an injectable collagenase used for selected adults with Dupuytren's contracture or Peyronie's disease. Coverage is subject to diagnosis-specific clinical criteria, prior authorization, documentation, administration requirements, and quantity limits. Dupuytren's contracture treatment is limited to up to 3 injections per cord at approximately 4-week intervals, while Peyronie's disease treatment is limited to one course with a maximum of 8 injections.

    Definitions

    Positive Tabletop Test
    TermPositive tabletop test
    DefinitionInability to simultaneously place the affected finger(s) and palm flat against a table
    Required timingPrior to initiating Xiaflex therapy
    Mandated Off-Label Use
    TermMandated off-label use
    Drug statusThe drug is approved by the Food and Drug Administration (FDA)
    Recognized evidenceThe off-label use is recognized in a statutorily recognized standard reference compendium or published peer-reviewed medical literature

    Xiaflex Quantity Limits

    Xiaflex for Dupuytren's Contracture
    Dose0.58 mg per injection
    Per-hand limitUp to 2 injections per hand
    Maximum per cordUp to 3 injections per cord
    Administration intervalApproximately 4-week intervals
    Xiaflex for Peyronie's Disease
    Dose0.58 mg for each plaque formation
    ScheduleOnce on each of 2 days, given 1 to 3 days apart, every 6 weeks for 4 cycles

    Administration Requirements

    Note

    Use an experienced Dupuytren’s provider

    Administer Xiaflex in the office by a healthcare provider experienced in hand injection procedures and treatment of Dupuytren’s contracture.

    • The administering provider must have experience with injection procedures of the hand and Dupuytren’s contracture treatment.
    Note

    Use a qualified Peyronie’s provider

    Administer Xiaflex in the office by a healthcare provider experienced in treating urological disease who has completed the Xiaflex REMS program requirements.

    • Verify completion of the Xiaflex REMS program requirements before administration.
    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyCollagenase Clostridium Histolyticum (Xiaflex)
    Policy CodePolicy ID_CHS_30432026_1126
    Change TypeNo material change
    Effective DateJan 30, 2027
    Next Review DateN/A
    Key ActionSubmit diagnosis-specific chart notes or medical records and, for continuation requests, the member's total number of prior injections for prior authorization review.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyContinuation TherapyClinical ThresholdsPrior Authorization and DocumentationPolicy BackgroundDefinitionsXiaflex Quantity LimitsAdministration Requirements
    Adult age: The member is 18 years of age or older.>=18 years
  1. Treatment-course limit: The member will receive a maximum of one treatment course with a maximum of 8 injections total, including injections received during any previous treatment.one course; maximum 8 total injections
  2. Adult age: The member is 18 years of age or older.>=18 years
  3. Injection limit: The member will receive no more than 3 injections per cord, administered 4 weeks apart, as part of the current treatment.up to 3 injections per cord, 4 weeks apart
  4. Peyronie's disease initial therapy

    Authorization for 12 months may be granted when all of the following criteria are met.

    • Stable disease: The member has stable Peyronie's disease without clinical changes, such as worsening curvature, for at least 3 months.stable for at least 3 months
    • Plaque and curvature: The member has a palpable plaque and curvature deformity of at least 30 degrees and no more than 90 degrees before initiating Xiaflex therapy.30-90 degrees
    • Intact erectile function: The member has intact erectile function, with or without medication.
    • Adult age: The member is 18 years of age or older.>=18 years
    • Treatment-course limit: The member will receive a maximum of one treatment course with a maximum of 8 injections total, including injections received during any previous treatment.one course; maximum 8 total injections

    Peyronie's disease continuation

    Authorization for 12 months may be granted for continuation when all of the following criteria are met.

    • Meets coverage criteria: The member meets all requirements in the coverage criteria section.
    • Continuation curvature: The member has curvature deformity of at least 15 degrees at the time of the continuation request.at least 15 degrees
    • Remaining injections: The member has received fewer than 8 injections total, including injections received during any previous treatment.less than 8 total injections
    Peyronie's Disease Continuation Threshold
    ConditionPeyronie's disease
    Curvature at continuationAt least 15 degrees
    Assessment timingAt the time of the continuation request
  5. Peyronie's disease: Chart notes or medical records indicating palpable plaque, curvature, and intact erectile function for new starts and continuation; for continuation, also document the number of injections the member has received.
  6. Documentation Required

    Prescriber Qualifications

    Xiaflex must be administered by a qualified healthcare provider with the required specialty experience and, when applicable, completion of the Xiaflex REMS program requirements.

    • Dupuytren's contracture: The provider must be experienced in hand injection procedures and in treating Dupuytren's contracture.
    • Peyronie's disease: The provider must be experienced in treating urological disease and must have completed the Xiaflex REMS program requirements.
    Denial Risk

    Unapproved or Unsupported Indication

    Indications other than the specified FDA-approved uses are considered experimental/investigational and not medically necessary, creating a denial risk.

    • Covered FDA-approved indications are adult Dupuytren's contracture with a palpable cord and adult men's Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.
    Denial Risk

    Cosmetic Use Excluded

    Coverage will not be provided for cosmetic use, including cellulite-reduction treatment.

    • Cosmetic use is excluded from coverage.
    Denial Risk

    Criteria or Treatment Limits Must Be Met

    Authorization may be denied when the indication-specific clinical criteria, age requirements, treatment-course limits, or continuation requirements are not met.

    • Dupuytren's contracture—initial: The member must have a finger flexion contracture with a palpable cord in a metacarpophalangeal or proximal interphalangeal joint; contracture of at least 20 degrees; a positive tabletop test, defined as inability to place the affected finger(s) and palm flat against a table simultaneously; age 18 or older; and no more than 3 injections per cord, 4 weeks apart, during the current treatment.
    • Peyronie's disease—initial: The member must have stable disease without clinical changes, such as worsening curvature, for at least 3 months; a palpable plaque and curvature deformity of at least 30 degrees and no more than 90 degrees before therapy; intact erectile function with or without medication; age 18 or older; and no more than one treatment course with a maximum of 8 injections total, including injections from previous treatment.
    • Dupuytren's contracture—continuation: The member must meet all coverage criteria, continue treatment for the same cord, and have received fewer than 3 injections total per cord, 4 weeks apart. A new cord or a previously treated cord following recurrence must meet all coverage criteria.
    • Peyronie's disease—continuation: The member must meet all coverage criteria, have curvature deformity of at least 15 degrees at the continuation request, and have received fewer than 8 injections total, including injections from any previous treatment.
    Applicable jurisdictionTennessee
    Maximum lifetime injections8 injections